Nanomol
    Technologies

  • The company
  • Successful cases
  • R+D
  • Clients
  • News
  • Contact

    Particle
    technologies

  • Delos enabled products
  • Benefits and advantages
  • Partnering
  • Delos nanovesicles
  • Solid particulate materials

    Contract
    analysis

  • Services
  • Analysis
  • Quality
  • Expertise and equipment
Back to the gallery

News

NEW DELOS NANOMEDICINE FOR THE TOPICAL TREATMENT OF COMPLEX WOUNDS
13 April 2021

NEW DELOS NANOMEDICINE FOR THE TOPICAL TREATMENT OF COMPLEX WOUNDS

A success case of reformulating a protein with therapeutic skin regeneration activity, to enhance its stability, delivery, and efficacy

 

An article titled "Recombinant Human Epidermal Growth Factor/Quatsome Nanoconjugates: A Robust Topical Delivery System for Complex Wound Healing" has been recently published in March 2021 in Advanced Therapeutics Journal (Wiley Online Library). In this paper the development and deep characterization of new DELOS Nanovesicles are described as a potential nanomedicine for the topical treatment of complex wounds, particularly diabetic foot ulcers and venous leg ulcers.

 

In the publication a soft, reliable, and scalable method based on our proprietary DELOS platform is reported for obtaining these nanoconjugates of recombinant human epidermal growth factor and DELOS nanovesicles. These nanoconjugates exhibit appropriate values of the major critical quality attributes of colloidal nanomedicines, such as controlled and narrow nanoscopic particle size distribution (which play important roles in determining their stability), drug loading, drug release, drug protection, targeting ability, and bioactivity. Also, they exhibit a dual action by 1) inbuilt antimicrobial activity preventing infections and 2) promoting regeneration of granulation tissue and re-epithelialization with complete closure of complex wounds.

The article has been authored by researchers from Nanomol Technologies SL, Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Center for Genetic Engineering and Biotechnology (CIGB), Aarhus University and Leitat Technological Center. https://doi.org/10.1002/adtp.202000260

 

Related
news

NANOMOL TECHNOLOGIES IS OFFICIAL PARTNER OF 12TH GLOBAL DDF SUMMIT DRUG DELIVERY & FORMULATION 16 March 2021

NANOMOL TECHNOLOGIES IS OFFICIAL PARTNER OF 12TH GLOBAL DDF SUMMIT DRUG DELIVERY & FORMULATION

SANTI SALA,  CEO AND COFOUNDER OF NANOMOL TECHNOLOGIES, WILL PARTICIPATE ON JUNE 29 IN A TECH TRANSFER FORUM 23 June 2021

SANTI SALA, CEO AND COFOUNDER OF NANOMOL TECHNOLOGIES, WILL PARTICIPATE ON JUNE 29 IN A TECH TRANSFER FORUM

Nanomol Technologies is hiring a Process Engineer! 27 December 2022

Nanomol Technologies is hiring a Process Engineer!

come and visit us

NANOMOL TECHNOLOGIES, S.L.
Mòdul de Recerca B
UAB CAMPUS

08193 Bellaterra
Cerdanyola del Vallès
Barcelona
Spain

get in touch

T +34 935 868 963
INFO@NANOMOL-TECH.COM

follow us

Twitter Linkedin

terms of use

Privacy policy Legality

Copyright © 2023

Nanomol Technologies S.L.

Site by Suki

This website uses cookies.